What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement

Case Study | How Investing in C2 Keep Could Have Prevented $192K in Controlled Substance Violations

Case Study | How Investing in C2 Keep Could Have Prevented $192K in Controlled Substance Violations
Case Summary: The Consequences of Taking Shortcuts

In this case, an independently owned pharmacy in Connecticut was fined $192,000 in civil penalties for violations of the Controlled Substances Act. Following a DEA investigation, regulators determined that the pharmacy failed to maintain complete and accurate records of controlled substance activity from early 2022 through mid 2024.

Beyond the financial penalty, the pharmacy was placed under a mandatory three-year Corrective Action Plan designed to enforce ongoing safety and CSA compliance. While enforcement actions like this may seem uncommon, controlled substance violations tied to recordkeeping gaps and documentation errors occur far more frequently than many pharmacy owners realize. Read More >

C2 Keep

C2 Keep News & Announcements

C2 Keep is a cloud-based, fully integrated Controlled Substances Act (CSA) compliance, audit preparedness, and inventory management solution. Built by former pharmacy director Roland Achenjang, it addresses the challenges pharmacies experience firsthand. C2 Keep automates workflows, delivers real-time inventory visibility, strengthens security, and simplifies reporting. Today, C2 Keep helps more than 2,000 pharmacists and staff nationwide save time, reduce risk, and stay inspection-ready.

RXinsider Staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Case Study | How Investing in C2 Keep Could Have Prevented $192K in Controlled Substance Violations

Name
Address
Subscribe